ANGIOSARCOMA

This study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…

This early-stage trial tests whether giving a targeted drug (palbociclib) before immunotherapy (pembrolizumab) is safe and can help shrink tumors in people with certain soft tissue sarcomas. About 8 participants will receive the combination. The main goal is to check for side eff…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This study tests whether the drug regorafenib can help prevent bone sarcomas from coming back after initial treatment. About 168 people aged 12 and older with various bone sarcomas will be randomly assigned to take regorafenib for up to 12 months or to receive standard monitoring…

This phase 2 trial tests whether the drug regorafenib can help keep high-grade bone sarcomas from growing in patients who still have some disease after standard treatment. About 36 people aged 12 and older will take regorafenib daily for up to 12 months. The main goal is to see h…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About …

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

This study tests a new drug called QL1706 in 45 adults with advanced bone or soft tissue sarcoma that cannot be removed by surgery or has spread. Participants receive the drug every 3 weeks. The main goal is to see if the cancer stays stable for at least 12 weeks. Researchers wil…

This study is testing new drug combinations for breast cancer to see which ones work best for different tumor types. It involves up to 5,000 people with early-stage or locally advanced breast cancer. Researchers use MRI scans and tissue samples before surgery to predict treatment…

This study looks at how abnormal blood vessel growth (angiogenesis) contributes to various skin diseases like rosacea, psoriasis, and certain tumors. Researchers will collect skin samples from 85 volunteers aged 16 and older to analyze markers of angiogenesis. The goal is to bett…

This study is collecting tissue samples and medical data from 800 high-risk sarcoma patients to develop personalized treatment approaches. Researchers will analyze genetic and protein profiles to better predict which patients benefit from chemotherapy before surgery. The goal is …

This study follows 250 people with localized angiosarcoma, a rare cancer of blood vessels. Researchers will collect information on tumor features, patient history, and standard treatments used in everyday practice. The goal is to better understand the disease and guide future car…